Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow ...

Pfizer has a diversified portfolio, including successful vaccines and promising new drugs. Read more to see why I upgrade PFE ...

We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a ...

On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.57 which represents a decrease of $-0.53 or -2.03% from the prior close of $26.1. The stock opened at $26.1 and touched a low of ...

Pfizer has had its own issues with falling Covid-19 vaccine sales weighing on its stock performance over the recent years.

Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health ...

Today, Benzinga 's options scanner spotted 29 uncommon options trades for Pfizer. This isn't normal. The overall sentiment of these big-money traders is split between 31% bullish and 62%, bearish. Out ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Check the time stamp on this data. Updated AI-Generated Signals for Pfizer Inc. (PFE) available here: PFE.

BofA reinstated coverage of Pfizer (PFE) with a Neutral rating and $29 price target Uncertainty over COVID revenue streams plus a “tough” base ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Currently, Pfizer has a Zacks Rank of #2 (Buy), while Novo Nordisk has a Zacks Rank of #3 (Hold). This means that PFE's earnings estimate revision activity has been more impressive, so investors ...